Harmony Biosciences Holdings, Inc. (HRMY)

NASDAQ: HRMY · IEX Real-Time Price · USD
49.34
+0.50 (1.02%)
Feb 3, 2023, 4:00 PM EST - Market closed
1.02%
Market Cap 2.93B
Revenue (ttm) 400.76M
Net Income (ttm) 155.67M
Shares Out 59.32M
EPS (ttm) 2.56
PE Ratio 19.27
Forward PE 25.64
Dividend n/a
Ex-Dividend Date n/a
Volume 424,836
Open 48.93
Previous Close 48.84
Day's Range 48.13 - 50.42
52-Week Range 33.04 - 62.09
Beta 0.63
Analysts Buy
Price Target 67.19 (+36.18%)
Earnings Date Feb 27, 2023

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvani... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 19, 2020
Employees 180
Stock Exchange NASDAQ
Ticker Symbol HRMY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is $67.19, which is an increase of 36.18% from the latest price.

Price Target
$67.19
(36.18% upside)
Analyst Consensus: Buy
Stock Forecasts

News

7 Healthcare Stocks That Will Be Big Winners in 2023

Healthcare stocks performed well in 2022, driven by a number of factors. One of the main drivers was the ongoing COVID-19 pandemic, which continued to boost demand for healthcare products and services...

Other symbols: LLYMCKMRKNVOUNHVIR
5 days ago - InvestorPlace

2 Biotechs Making Waves With A Single Product in their Pipeline

Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.

Other symbols: CPRX
3 weeks ago - MarketBeat

Strength Seen in Harmony Biosciences Holdings, Inc. (HRMY): Can Its 5.1% Jump Turn into More Strength?

Harmony Biosciences Holdings, Inc. (HRMY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest fu...

3 weeks ago - Zacks Investment Research

HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN

PLYMOUTH MEETING, Pa. , Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializin...

1 month ago - PRNewsWire

HARMONY BIOSCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

PLYMOUTH MEETING, Pa. , Dec. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializi...

1 month ago - PRNewsWire

Why Harmony Biosciences (HRMY) Stock Might be a Great Pick

Harmony Biosciences (HRMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

2 months ago - Zacks Investment Research

HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 34th ANNUAL HEALTHCARE CONFERENCE

PLYMOUTH MEETING, Pa. , Nov. 9, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializin...

3 months ago - PRNewsWire

Harmony Biosciences Holdings, Inc. (HRMY) Beats Q3 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead f...

3 months ago - Zacks Investment Research

Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates

WAKIX® (pitolisant) Net Revenue of $117.2 Million for Third Quarter 2022 Increase of ~45% vs. the Same Period in 2021

3 months ago - GlobeNewsWire

HARMONY BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH PRADER-WILLI SYNDROME

PLYMOUTH MEETING, Pa. , Nov. 1, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative ther...

3 months ago - PRNewsWire

Analysts Estimate Harmony Biosciences Holdings, Inc. (HRMY) to Report a Decline in Earnings: What to Look Out for

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER 1, 2022

PLYMOUTH MEETING, Pa. , Oct. 18, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializi...

3 months ago - PRNewsWire

HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS

PLYMOUTH MEETING, Pa. , Sept. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative th...

4 months ago - PRNewsWire

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

PLYMOUTH MEETING, Pa. , Aug. 17, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company focused on delivering innovative therapie...

6 months ago - PRNewsWire

Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 42.50% and 7.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for ...

6 months ago - Zacks Investment Research

Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates

WAKIX® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs. the Same Period in 2021

6 months ago - GlobeNewsWire

HARMONY BIOSCIENCES ANNOUNCES DATE OF SECOND QUARTER 2022 FINANCIAL RESULTS

PLYMOUTH MEETING, Pa. , July 19, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializi...

7 months ago - PRNewsWire

7 No-Brainer Biotech Stocks to Add to Your Buy List

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first ...

Other symbols: BIIBCINCCRSPEBSVIGL
8 months ago - InvestorPlace

HARMONY BIOSCIENCES PRESENTS POST-HOC ANALYSIS OF WAKIX® (PITOLISANT) PIVOTAL DATA IN ADULTS WITH HIGH BURDEN OF NARCOLEPSY SYMPTOMS

PLYMOUTH MEETING, Pa. , June 6, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative ther...

8 months ago - PRNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Harmony Biosciences Holdings, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , May 5, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim i...

9 months ago - PRNewsWire

Harmony Biosciences Holdings, Inc. (HRMY) Beats Q1 Earnings Estimates

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 104% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for t...

9 months ago - Zacks Investment Research

Harmony Biosciences Reports First Quarter 2022 Financial Results and Business Updates

WAKIX® (pitolisant) Net Revenue of $85.3 Million for First Quarter 2022 Increase of 43% vs. the Same Period in 2021

9 months ago - GlobeNewsWire

HARMONY BIOSCIENCES INITIATES PHASE 3 TRIAL OF PITOLISANT IN ADULT PATIENTS WITH IDIOPATHIC HYPERSOMNIA

PLYMOUTH MEETING, Pa., April 27, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative the...

10 months ago - PRNewsWire

7 Best Biotech Stocks to Build Your Portfolio

Biotech stocks were some of the best performers at the start of the pandemic. More recently, though, they've vastly underperformed the broader market.

10 months ago - Kiplinger

HARMONY BIOSCIENCES OPENS APPLICATIONS FOR 2022 PROGRESS AT THE HEART PROGRAM

Program will award funding to select applications from non-profit organizations addressing disparities in rare neurological disease and sleep disorder communities PLYMOUTH MEETING, Pa. , April 7, 2022...

10 months ago - PRNewsWire